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Abstract An approach based on homology probing was used to 
clone a partial cDNA encoding a novel melatonin (ML) receptor 
(MLR) from chicken (Gallus domestlcus) brain. Based on availa- 
ble deduced amino-acid sequence, the chicken MLR (cMLR) 
displayed greater sequence homology to the frog (Xcnopus) MLR 
than cloned human/mammalian receptors, with overall identities 
of 73% and 66%, respectively. In order to gain functional expres- 
sion, a chimeric frog/chicken (flc)MLR was constructed in which 
the 5' end of the cMLR, including the N-terminus, TMI and part 
of the first intracellular loop was substituted by fMLR sequence. 
[12Sl]lodo-ML bound with high affinity (Ko of ~35 pM) to COS-7 
cells transiently expressing the flcMLR in a saturable and gua- 
nine nucleotide-sensitive manner with the following rank order of 
potency: 2-iodo-ML > ML > 6-CI-ML > $20750 > 6-OH-ML 
> $20642 > $20753 > N-acetyl-SHT >> S-HT. Estimated Ki 
values for these compounds at the flcMLR correlated well to 
those obtained in native chicken brain membranes. In line with 
the observed structural similarity to the fMLR, the flcMLR 
exhibited affinities for ML, 6-CI-ML and 6-OH-ML ~10-fold 
lower than mammalian receptors. Functionally, opposing interac- 
tions between ML and dopamine receptor signal transduction 
pathways were observed with ML potently inhibiting dopamine 
D1 A-receptor-mediated cAMP accumulation i  cells (HEK-293) 
transiently co-expressing these receptors. ¢MLR mRNAs were 
found expressed in chicken brain and kidney with trace levels 
observed in the lung. The availability of cloned vertebrate MLRs 
distinct at both the amino acid and pharmacological level from 
their mammalian counterparts may now allow for the identifica- 
tion of those amino-acid residues and structural motifs that regu- 
late ML-binding specificity and affinity. 
Key words': G-protein coupled; cAMP inhibition; Dopamine 
D 1 receptor 
I. Introduction 
Melatonin (ML), the primary hormone of the pineal gland, 
is thought o mediate many of its physiological nd behavioral 
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process via neural specific mechanisms. Thus, ML influences 
the regulation of circadian rhythms, functioning of the neuro- 
endocrine-reproductive axis, visual function, activity levels and 
sleep in both birds and mammals (for review, see [1-6]). The 
primary sites of action for these ML-mediated events are recep- 
tors located in the suprachiasmatic nuclei and pars tuberalis, 
the retina and paraventricular nucleus of the thalamus [7 12]. 
Based on pharmacological nd biochemical criteria two ML 
receptors (MLRs), termed ML~ and ML2, have been identified 
[2,13]. ML~ receptors are defined by their ability to bind 2- 
[125I]iodo-ML and various analogs with high affinity (pM) and 
to inhibit adenylyl cyclase activity [9,14~19]. In contrast, ML 2 
receptors display nanomolar affinity for iodo-ML, exhibit a 
pharmacological profile for ML distinct from the MLI receptor 
and appear to activate second messenger systems other than 
adenylate cyclase [20]. 
MLRs have been extensively characterized in G. domesticus 
due to the relatively high density and widespread istribution 
in both the brain and periphery [8,21-23]. In the retina, ML 
inhibits dopamine synthesis and release [24] with a pharmacol- 
ogical profile and rank order of potency corresponding to the 
high-affinity ML~ receptor [25] found in either the rabbit retina 
or other neuronal and peripheral tissues from the same or 
different species ([26,27] and see [2,13]). Moreover, in the retina, 
many opposing physiological nd regulatory actions between 
dopamine and ML have been documented (see [28] and refer- 
ences therein). These interactions do not appear estricted to 
the retina, however, but may be evidenced as well in the hypo- 
thalamus and the pituitary gland where dopamine and ML 
regulate hormone release [29,30]. Although the molecular 
mechanism(s) by which these putative opposing interactions 
occur are still unknown, possible cross-talk between ML and 
dopamine D 1 receptor-mediated signal transduction events has 
been suggested [28]. 
Recently, high-affinity ML~ receptor cDNAs were isolated 
and characterized from Xenopus laevis dermal melanophores 
[31] the pars tuberalis of sheep and human hypothalamus [32]. 
As with multiple dopamine receptors [33,34], MLRs are mem- 
bers of a superfamily of genes encoding G-linked receptors and 
based on their deduced amino-acid sequence and conservation 
of structural motifs appear to form a new subclass within this 
family. 
As a step towards examining the molecular mechanisms by 
which these receptors transduce ML's numerous physiological 
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effects and its regulation of dopaminergic signal cascades in 
both the brain and periphery, we report here on the molecular 
characterization f  a chicken brain partial cDNA appearing to 
encode a novel MLR.  
2. Materials and methods 
2.1. Cloning of partial cMLR 
A chicken brain eDNA library (Clontech) was screened with a 3:p_ 
labeled cDNA fragment (-444 bases) encoding putative transmembrane 
(TM) domains TM4-7 of the Xenopus brain MLR obtained by RT- 
PCR. ~8 × 105 independent clones were screened under reduced strin- 
gency conditions as previously described [35]. Briefly, duplicate nylon 
filters (Dupont/NEN) were hybridized overnight at 42°C in a solution 
containing 40% formamide, 50 mM Tris-HCl, pH 7.5, 0.1% sodium 
pyrophosphate, 0.2% BSA, 0.2% polyvinylpyrolidine, 0.2% Ficoll 
400,000, 1% SDS, 0.1% NaC1, 0.1 mg/ml sheared salmon-sperm DNA 
and a nick-translated (Amersham) 32p-labeled Xenopus probe (1.5 × 10 6 
cpm/ml). Filters were washed 2 × in 2 × SSC/I% SDS for 20 min at 
55°C and exposed to autoradiography. One positive clone (~3 kb) was 
isolated and following tertiary screening was analysed by restriction 
mapping and Southern blot analysis. A strongly hybridizing l-kb PstI 
fragment was subcloned into pSP73 (Promega), sequenced in both 
directions using the Sanger dideoxy-chain termination method with 
7-deaza-dGTP and Sequenase V 2.0 (USB) and with either specific 
internal (Biotechnology Service Center HSC, Toronto, Canada) or 
SP6/T7 primers. 
2.2. Construction of chimeric frog/chicken MLR 
In order to obtain functional receptor activity, we adopted a three 
primer PCR fusion strategy [36] to construct a cMLR chimeric receptor 
containing the 5' region of the cloned Xenopus MLR [31]. Briefly, a 
region within TM2 (a.a...ADLVVA...) of both the frog and chicken 
cDNAs that displays 83% nucleotide sequence identity was chosen to 
design two complementary primers (chicken primer A: 5'-GCC GAT 
CTG GTG GTG GCC TTG TAT-3' and primer B: 3'-AGA TAA CGG 
CTA GAC CAC CAC CGG-5' for Xenopus). To amplify the 5' region 
of the Xenopus MLR, eDNA in pcDNA1 (obtained from Dr. S.M. 
Reppert) was subjected to PCR using synthetic primer B and the vector 
primer T7. The entire coding sequence of the cMLR eDNA (encom- 
passing TM2 to Y-untranslated region) was subjected to PCR using 
primer A and a primer encoding Y-untranslated sequence (primer C: 
5'-AAC ATT CGA ACT CTA TCA-3'). - 1/Jg DNA and 1/Jg of each 
appropriate primer were submitted to 30 cycles of the PCR (1 min at 
94°C, 1.5 min at 58°C and 1.5 min at 72°C; Perkin-Elmer/Cetus) with 
2.5 U Taq polymerase. Amplified DNA (frog ~200 bp and -900 bp for 
cMLR) from both reactions were recovered from a 0.8% low-melt 
agarose gel, purified through GlassMAX (Gibco/BRC) spin columns, 
mixed and subjected to a second round of PCR using only T7 and C 
oligonucleotides as primers under conditions described above. An am- 
plified ~ 1.2-kb product was subcloned into pBluescript SK-. To confirm 
appropriate splice fusion and the absence of spurious PCR-generated 
nucleotide rrors, the entire chimeric Xenopus/G. domesticus amplified 
construct (termedflcMLR) was resequenced asdescribed above. 
2.3. Cell transfection and ligand-b&ding analysis 
For transient expression studies, the chimericflcMLR was subcloned 
into the expression vector pCDNA3 (Promega). COS-7 cells were trans- 
fected with cesium chloride-purified DNA constructs by electropora- 
tion (80 pg DNA/2.5 x 107 cells; 48/2, 135 mA, 500 pF), placed into 
150-mm plates and cultured for 4-5 days as previously described [37]. 
COS-7 cells were maintained in Dulbecco's alpha-modified Eagle's 
medium supplemented with 10% fetal calf serum at 37°C and 5% COz. 
The cells were collected and pelleted at 1000 rpm for 10 min at 4°C and 
stored at -80°C until use. 
[~:sI]Iodo-ML (2000 Ci/mmol) was prepared as previously described 
[22]. Cells were thawed, washed and resuspended in 50 mM Tris-HC1, 
5 mM MgCI2, pH 7.4, at a concentration f ~300pg protein/ml and 
incubated (50/11) with increasing concentrations of [125I]iodo-ML (2 
200 pM), in a total reaction vol. of 200 ml for 90 min at room temper- 
ature under constant shaking. For competition experiments, cells were 
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Fig. 1. Deduced amino-acid sequence alignment of the avian MLR and other cloned members of the mammalian and vertebrate MLR family. Boxed 
and shaded areas denote amino-acid residues conserved between the avian MLR and its vertebrate/mammalian counterparts [31,32]. Putative TM 
domains are demarcated byboxed regions. Potential phosphorylation sites for protein kinase A (cAMP-dependent) and protein kinase C are indicated 
by closed circles (e) and closed (m) squares, respectively. Single-letter amino-acid code used. 
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incubated with 30-40 pM [~25I]iodo-ML in the presence of varying 
concentrations (10 ~-'-10 5M) of competing agents or guanosine-5'-O- 
(Y-thiotriphosphate) (GTPTS) and assayed for ligand-binding activity. 
Non-specific binding was defined in the presence of 1/,tM ML. Assays 
were terminated by the addition of 3 ml Tris-HCl buffer (4°C) and 
immediate vacuum filtration through Whatman GF/B filters using a 
M48R cell harvester. Filters were washed 2 x with 3 ml cold buffer and 
bound radioactivity measured by a ?'-counter at 74% efficiency• In 
order to directly compare [~:sI]iodo-ML-binding characteristics of the 
cloned J /cMLR expressed in COS-7 cells with native chicken brain 
MLRs, we assayed both receptor activities in parallel. Brains from 
G. domesticus were homogenized in ice-cold buffer [22] and assayed for 
MLR-binding activity as described above. Protein concentrations were 
determined as previously described [22]. Ligand-binding data were 
analysed by L1GAND or Kaleidagraph (Abelbeck Software) as previ- 
ously described [35,37]. 
2.4. cAMP accumulation 
HEK-293 cells were transiently co-transfected withf lcMLR cDNA 
and the recently cloned chicken dopamine DIA receptor [38] using 
calcium phosphate precipitation as described [39], placed in 24-well 
plates and grown for 4 days in Dulbecco's modified Eagle's medium 
supplemented with 10% FBS [Gibco). Cells were washed with 0.5 ml 
prewarmed ~-MEM containing 0.5 mM 3-isobutyl-l-methylxanthine 
and 1 ,uM propranolol and co-incubated with varying concentrations 
of ML (10 pM 100 riM) and forskolin (1 ,uM) or the dopamine DI 
selective agonist, SKF-82526 (1 pM) for 15 min at 37°C. Reactions 
were terminated by the addition of 500/11 0.2 N HCI, cellular debris 
pelleted by centrifugation at500 x g and supernatants (12.5 pl) assayed 
for cAMP formation by R1A (Amersham) as previously described [35]. 
Mock-transfected (plasmid alone) or untransfected cells did not display 
endogenous binding or adenylate cyclase activity (data not shown). 
2.5. RT-PCR analysis of eMLR mRNA 
Total RNA was isolated from chicken brain optic tectum, cerebel- 
lum, kidney and lung tissue using TRISOLV (Biotecx Laboratories, 
Houston, TX) as previously described [35]. ~ 1 pg total RNA from each 
tissue was subjected 1o first-strand cDNA synthesis with 25 pmol of 
oligo(dT) (Perkin-Elmer/Cetus) and 200 U Superscript reverse tran- 
scriptase (Life Technologies) for 30 min at 42°C. The RNA template 
was removed by the addition of 5 U RNase H for 10 min at 55°C. 
Single-stranded cDNA samples were purified through GlassMAX spin 
columns (Life Technologies) and subjected to 30 cycles of PCR ampli- 
fication (94°C, 1 min; 58°C, 1.5 min; 72°C, 1.5 min) using 0.5 pg of a 
cMR-specific internal oligonucleotide primer (5'-GAA ATG GCA 
CCA AAA GTT-3') encoding sequences within the fourth extracellular 
loop (MAPKV) and one primer in the 3'-untranslated region (5'-TGA 
TAG AGT TCG AAT GTT-Y) and 2 U Taq DNA polymerase (Perkin- 
Elmer/Cetus). A DNase control group in which reverse transcriptase 
was not added was processed in parallel. Amplified products were 
electrophoresed in a 1% agarose gel, transferred to nylon membranes 
and probed with 7[~-'P] end-labeled oligonucleotide internal to the 
flanking primers (5'-CCT TAA TTC AAT AAT ATA-Y). Blots were 
- - - - )  
Fig. 2. Pharmacological specificity of [J-'51]iodo-ML-binding to COS-7 
cells expressing the chimeric avian J/cMLR. COS-7 cells were trans- 
fected with a cDNAs encoding the chimericJ/cMLR and assayed for 
receptor activity as described in section 2. (A) Representative curves are 
illustrated for the concentration-dependent inhibition of[~25I]iodo-ML - 
binding (20~,0 pM) to expressedflcM LRs (~ 25 40 fmol/mg protein) by 
ML agonists and other agents as listed. Estimated inhibitory constants 
(K.) for these compounds, included in Table 1, were determined by 
LIGAND or KALEIDAGRAPH and are representative of at least two 
independent experiments each conducted in duplicate and which varied 
by <10%. Pharmacological homology between thejlcMLR and (B) the 
native chicken brain and (C) cloned Xenopus MLR. Correlational plots 
of estimated inhibitory constants (KJ of various ML agonists and 
agents to inhibit [i-,si]iodo_ML_binding tothe clonedflcM LR expressed 
in COS-7 cells with that of chicken brain membranes and of the Xenopus 
MLR expressed in COS-7 cells. The line of identity or equimolarity is
indicated. K, values for Xenopus receptors were taken from [31]. 
washed with 2 x SSC, 1% SDS for 15 rain at room temperature followed 
by a 15-min wash at 42°C and exposed for autoradiography overnight 
at -70°C. 
3. Results and discussion 
One hybridizing clone (~3 kb) was isolated l¥om a chicken 
brain cDNA library and found, after nucleotide sequence anal- 
ysis, to contain a long open reading frame of 869 nucleotides, 
displaying marked deduced amino-acid sequence homology to 
cloned members of the G-protein-linked MLR family [31,32]. 
The clone, however, did not contain the entire 5' end of the 
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Fig. 3. cAMP accumulation following avian flcMLR stimulation. 
HEK-293 cells transiently co-expressing the G. domesticus dopamine 
D 1A and theflcMLR at a ratio of ~ 3:1 were assayed for cAMP accumu- 
lation as described insection 2. Following treatment with 1 pM SKF- 
82526, avian D 1A receptor stimulates cAMP production ~20-fold above 
basal levels. Dopamine D1 receptor stimulation ofcAMP accumulation 
was inhibted, in a concentration-dependent ma ner by ML with maxi- 
mal inhibtion (-60%) observed at 100 nM. Results hown are represen- 
tative of at least hree independent experiments each conducted in 
duplicate. HEK-293 cells transfected with either dopamine D1A or 
cMLRs alone did not show this interaction. Incontrasl to the effect of 
ML, dopamine D1A-mediated stimulation ofadenylate cyclase isinhib- 
ited by the selective D 1 receptor antagonist, SCH-23390 (1/~M) to basal 
levels (~4 pmol/well). 
receptor but contained sequence information encoding the first 
cytoplasmic loop (beginning at residues GN) to the 3' end of 
the coding region (Fig. 1). Repeated attempts, using a variety 
of techniques, to obtain the 5' coding region of the cMLR 
cDNA were unsuccessful (data not shown). The 5' end of the 
cMLR cDNA, including the N-terminus and TM1, appears to 
have been interrupted by intronic sequences (>2 kb) at a posi- 
tion identical with that reported for mammalian MLRs [32]. 
As depicted in Fig. 1, overall amino-acid sequence identities 
of the cMLR were 73% identical with that of the Xenopus MLR 
and 67% identical with sheep and human MLRs. Within puta- 
tive TM domains, amino-acid sequence identities were consid- 
erable higher with the cMLR displaying 81 and 80% identity 
to Xenopus and mammalian receptors, respectively. Consistent 
with the contention that MLRs may represent a distinct sub- 
class of the G-protein-linked receptor family is the conservation 
of the NRY sequence motif after TM3 and the NAXIY motif 
found in TM7. Also conserved are consensus sequences for 
phosphorylation by protein kinase A and protein kinase C 
within the third intracellular loop and C-terminal tail, respec- 
tively, regions thought o be involved in receptor desensitiza- 
tion and regulation [40]. Areas of significant sequence diver- 
gence are restricted to putative intra- and extracellular loops 
and the C-terminal tail. Analysis of deduced amino-acid se- 
quence homologies of these regions of the cMLR reveals iden- 
tities of 65 and 56% to Xenopus and mammalian receptors, 
respectively. Despite the strong observed sequence homology, 
the cMLR C-terminus ends at a position identical with those 
of mammalian receptors and is 65 amino-acid residues horter 
than the Xenopus receptor. 
In order to gain functional expression, we adopted a three 
primer PCR fusion strategy to construct a chimeric cMLR. 
Thus, by fusing the N-terminal, TM1 and part of the first 
intracellular loop of the Xenopus MLR (amino-acid residues 
1 79) to the cMLR, a full-length MLR cDNA, termedf/cMLR, 
was made. We chose to fuse the 5' end of the Xenopus, rather 
than the cloned human MLR, based on the observed greater 
nucleotide and deduced amino-acid sequence homology dis- 
played by the cMLR with the Xenopus receptor elative to its 
mammalian counterparts ( ee above). The entire flcMLR was 
then resequenced and found to contain o PCR-generated nu- 
cleotide substitutions/additions/deletions. 
We compared the ability of the flcMLR to mimic native 
neuronal avian cMLRs, in terms of its exhibited pharmacologi- 
cal profile and ligand-binding specificity. COS-7 cells tran- 
siently expressing the chimeric flcMLR bound [125I]iodo-ML 
(2-200 pM) in a concentration-dependent and saturable man- 
ner to a single class of binding site with an estimated Kd of 
35 + 6 pM and B .... value, ranging from 20 to 90 fmol/mg 
protein, respectively. Binding of [~25I]iodo-ML (35 pM) to COS- 
7 cells expressing theflcMLR was reduced by ~70% following 
the addition of 200 pM GTPTS (control: 47 + 8; GTPgS 
treated: 16 + 2 fmol/mg protein), suggesting that expressed re- 
ceptors are functionally coupled to endogenous subtype-spe- 
cific G-proteins. Virtually identical results were obtained in 
native membranes prepared from avian brain (data not shown). 
Moreover, as depicted in Fig. 2A, [~25I]iodo-ML-binding to 
COS-7 cells expressing theflcMLR was inhibited in a concen- 
tration-dependent a d uniphasic manner (as indexed by Hill 
coefficients close to unity) by a variety of melatonergic agonists 
and agents with a rank order of potency and pharmacological 
profile clearly consistent with a neuronal ML-like receptor. 
Thus, of all the compounds tested iodo-ML was the most 
potent inhibitor followed by 6-CI-ML > $20750 (N-[2-(7- 
methoxy-1-naphthyl)ethyl]crotonamide) > 6-OH-ML > $20642 
(N-[2-(7-methoxy-l-naphthyl)ethyl)cyclobutane) > $20753 (N- 
(propyl-[2-(7-methoxy-l-naphthyl)ethyl]urea) > N-acetyl-sero- 
tonin >> 5-HT. Estimated K~ values for these agents are listed 
in Table 1. Moreover, as illustrated in Fig. 2B, the estimated 
Table 1 
Inhibitory constant (K~) values of various compounds for [~2sI]iodo- 
ML-binding to the cloned chicken tic MLR expressed inCOS-7 cells 
or to native brain membranes 
Compound Cloned Native Cloned/Native 
Ki (nM) 
2-iodo-ML 0.023 0.033 0.7 
ML 2.4 1.6 1.5 
6-chloromelatonin 3.8 2.2 1.7 
S-20750 35 17 2.0 
6-hydroxymelatonin 49 42 1.2 
S-20642 58 33 1.7 
S-20753 184 93 1.9 
N-Acetyl serotonin 872 500 1.7 
Serotonin >10,000 >10,000 1.0 
Inhibitory constants (K3 of various melatonin agonists and agents for 
(L25I]iodo-binding to either COS-7 cells tranfected with the avian f/c 
M LR cDNA or to chicken brain membranes are listed in order of their 
potency for the cloned receptor. Values represent the means of at least 
two independent experiments each conducted in duplicate with esti- 
mated K~ values determined by LIGAND and which varied < 10%. 
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Fig. 4. Tissue-specific distribution of avian MLR mRNA. Samples (1 
pg) of G. domesticus brain, kidney and lung total mRNA were subjected 
to reverse transcriptase using oligo(dT) followed by PCR using two 
additional oligonucleotides a described in section 2. Amplified cDNA 
products were Southern-blotted and probed with a 32p-labeled oligonu- 
cleoide internal to the PCR fragment. MLR transcripts ofthe appropri- 
ate size were evident in chicken forebrain, cerebellum and kidney with 
trace amounts evident in lung. DNase controls with no reverse tran- 
scriptase ( ) are located to the right of each hybridizing PCR product. 
Size of amplified and radiolabeled PCR products (bp) are shown. Blots 
were subjected to autoradiography for~ 12 h. 
inhibitory constants (Ki) obtained for the inhibition of 
[~25I]iodo-ML-binding by a series of compounds at the native 
avian MLR correlate strongly (r -- 0.989) with Ki values ob- 
tained for these agents at the cloned chimericflcMLR with a 
virtual one to one correspondence in estimated receptor affin- 
ity. These data clearly suggest that the addition of the 5' coding 
sequence of the Xenopus MLR does not appreciable alter the 
ligand-binding characteristics of the cloned chicken brain 
MLR. 
There are some unique pharmacological characteristics that 
appear to differentiate vertebrate (frog/chicken) MLRs from 
their mammalian homologs (sheep/human). Thus, while all 
cloned MLRs, when expressed in COS-7 cells, display identical 
affinities for iodo-ML, both the human and sheep MLRs [32] 
exhibit the inherent ability to bind ML, 6-hydroxy-ML and 
N-acetyl serotonin with higher affinity than either cloned frog 
[31] or chimeric flcMLRs. As depicted in Fig. 2C, and con- 
sistent with our proposed classification of these receptors based 
on amino-acid sequence homologies listed in Fig. 1, of all the 
agents tested each exhibited affinities for the Xenopus MLR 
that were virtually identical with those obtained from the ex- 
pressed chimeric G. domesticus MLR. In marked contrast, di- 
rect comparison of the estimated K~ values of numerous agents 
at the f lcMLR with sheep or human receptors [32], although 
correlative, clearly reveals numerous compounds displaying 
from 5-10-fold higher affinity for mammalian receptors. Given 
the lack of strong observed sequence and pharmaclogical ho- 
mology between the cloned vertebrate and mammalian MLRs, 
we suggest hat the cloned chicken and frog MLRs are not 
merely species orthologues of mammalian receptors. Indeed, 
we have isolated a human genomic lone [Liu, F., Brown, G.M 
and Niznik, H.B. unpubl, data; also see Genbank Accession 
U25341 (Reppert, S.M. et al.)] which upon sequence analysis 
displays higher deduced amino-acid sequence homology to the 
cloned chicken and frog MLRs than those of mammalian origin 
[32]. 
In order to assess the ability of the f/cMLR to functionally 
inhibit adenylate cyclase activity, we co-transfected HEK-293 
cells with both theflcMLR and the recently cloned G. domesti- 
cus dopamine D1A receptor which stimulates the activity of 
adenylate cyclase in response to selective D1 agonists [38]. As 
summarized in Fig. 3, in cells co-expressing these receptors the 
potent D1 receptor agonist SKF-82526 (1 /.tM) stimulated 
cAMP accumulation ~20-fold over basal evels. Co-incubation 
of cells with increasing concentrations of ML inhibited opam- 
ine D 1-stimulated cAMP accumulation i these cells. At a con- 
centration of 10-100 nM ML an ~60% decrease indopamine D1 
receptor-mediated adenylate cyclase activity was observed. No 
endogenous MLR activity was observed in cells only expressing 
D1 receptors and while 1/.tM forskolin stimulated the produc- 
tion of cAMP-  100-fold over basal evels the addition of 100 nM 
ML resulted in an -30% decrease of forskolin stimulated cAMP 
accumulation in HEK-293 cells transiently expressing the 
cloned f lcMLR (data not shown). Although it is unclear 
whether ML- and dopamine Dl-like receptors co-exist in the 
same neurons, evidence for functional ML and dopamine D1 
receptor cross-talk regulating the activity of adenylate cyclase 
in cultured retinal cells has recently been documented [19,28]. 
The data on cloned receptors provide direct molecular evidence 
for the existence of functional ML-dopamine receptor interac- 
tions at the level of the single cell. The exact subtype-specific 
G-protein ~ (Gi/Go) or fl7 subunits by which MLR activation 
inhibits D1 receptor-mediated cAMP accumulation or whether 
other cloned members of the Dl-l ike receptor family [35,38,41], 
particularly the dopamine D5 receptor [39,42], are differentially 
and functionally regulated by specific MLRs is currently un- 
known. The use of knock out mice for either subtype-specific 
dopamine receptors [43] or MLRs, when they become availa- 
ble, may help to identity the functional physiological nd devel- 
opmental interactions between these two systems. 
As depicted in Fig. 4, RT-PCR analysis of MLR mRNA 
indicates expression in both chicken brain and peripheral tis- 
sues. Southern blots of RT-PCR-amplified products reveals 
strongly hybridizing bands in chicken forebrain and cerebel- 
lum. Similar levels of expression were seen in chicken kidney. 
In contrast, the chicken lung revealed trace amounts of MLR 
mRNA. The mRNA distribution patterns of the cloned cMLR 
are in line with the known distribution patterns of native recep- 
tors in avian brain and peripheral tissues, as determined 
by both ligand-binding and receptor autoradiography 
[23,26,27,44]. In situ hybridization analysis will be necessary to 
clearly define the tissue-specific and cellular distribution profile 
of MLR mRNAs in this species. 
We provide molecular evidence for the existence of a chicken 
brain MLR variant exhibiting amino-acid sequence and phar- 
macological profiles distinct from mammalian receptor coun- 
terparts. Moreover, we show that the chimeric chicken MLR 
functionally inhibits second messenger dopamine D 1 receptor- 
mediated responses. The availability of species- and receptor- 
specific MLR cDNAs may provide a more practical approach 
by which to identify sequence-specific motifs that underlie the 
expression of unique high-affinity MLR characteristics. Given 
the degree of exhibited sequence homology among members of 
the MLR family, observed species- and receptor-specific phar- 
macological profiles would suggest that changes in key amino- 
acid residues may translate into major shifts in potency and 
substrate specificity. As such, the construction of interspecies 
receptor chimeras may aid in the identification of those regions 
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involved in the unique pharmacological specificity of MLRs 
and may ultimately provide the molecular basis for the rational 
design of therapeutic ompounds acting at these receptors for 
the treatment of various ML-induced endocrine and neuropsy- 
chiatric diseased states [5,6]. 
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